A review examines endogenous, plant-derived, and synthetic cannabinoids as potential treatments for traumatic brain injury and related neuropathologies.
Neurologists, TBI researchers, athletes concerned about concussion, military medicine specialists, and neuroscience researchers.
20% persistent symptomsNo approved treatments exist for TBI, where 20% of mild cases have symptoms lasting months
What the researchers found
Preclinical and early clinical evidence suggests cannabinoids may have neuroprotective effects following traumatic brain injury, with potential mechanisms including reducing neuroinflammation, excitotoxicity, and oxidative stress.
Why it matters
TBI is common and often devastating, with no approved pharmaceutical treatments that improve outcomes. Cannabinoids represent a promising but understudied therapeutic avenue that could address multiple injury mechanisms simultaneously.
The numbers in context
Approximately 20% of patients with mild TBI have symptoms persisting for months, and there are currently no approved pharmaceutical interventions that improve TBI outcomes.
How the study worked
Review of preclinical and clinical research on endogenous, plant-derived, and synthetic cannabinoids in TBI and related neuropathologies.
Who was studied
Preclinical models and clinical observations of traumatic brain injury patients.
What this study cannot tell us
Most evidence is preclinical; timing of cannabinoid administration post-injury is critical and poorly defined; different cannabinoid types may have opposing effects.
How to read the evidence
Review of mostly preclinical evidence; clinical TBI-cannabinoid trials are in early stages.
When this study was published
Recent review capturing current state of cannabinoid-TBI research.
The bigger picture
The endocannabinoid systems role in neuroprotection following brain injury represents a compelling therapeutic target, particularly given the complete lack of approved TBI treatments.
Replication
Builds on growing preclinical evidence for cannabinoid neuroprotection; clinical translation remains early-stage.
Funding
Not specified
Conflicts of interest
Not specified
Questions still open
- Which cannabinoids are most neuroprotective after TBI?
- What is the optimal timing for cannabinoid administration post-injury?
- Could pre-injury endocannabinoid levels predict recovery?
Read the original research
Cannabinoids in traumatic brain injury and related neuropathologies: preclinical and clinical research on endogenous, plant-derived, and synthetic compounds.
Journal of neuroinflammation, 20(1), 77
Citation
Lins, Brittney R; Anyaegbu, Chidozie C; Hellewell, Sarah C; Papini, Melissa; McGonigle, Terence; De Prato, Luca; Shales, Matthew; Fitzgerald, Melinda. (2023). Cannabinoids in traumatic brain injury and related neuropathologies: preclinical and clinical research on endogenous, plant-derived, and synthetic compounds.. Journal of neuroinflammation, 20(1), 77. https://doi.org/10.1186/s12974-023-02734-9